Valneva (VALN) Competitors $9.57 -0.11 (-1.10%) As of 10/24/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. ADMA, INDV, AAPG, XENE, QURE, ZLAB, CGON, RARE, IRON, and AMRXShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include ADMA Biologics (ADMA), Indivior (INDV), Ascentage Pharma Group International (AAPG), Xenon Pharmaceuticals (XENE), uniQure (QURE), Zai Lab (ZLAB), CG Oncology (CGON), Ultragenyx Pharmaceutical (RARE), Disc Medicine (IRON), and AMNEAL PHARMACEUTICALS (AMRX). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors ADMA Biologics Indivior Ascentage Pharma Group International Xenon Pharmaceuticals uniQure Zai Lab CG Oncology Ultragenyx Pharmaceutical Disc Medicine AMNEAL PHARMACEUTICALS Valneva (NASDAQ:VALN) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Which has more risk & volatility, VALN or ADMA? Valneva has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Does the media favor VALN or ADMA? In the previous week, ADMA Biologics had 2 more articles in the media than Valneva. MarketBeat recorded 9 mentions for ADMA Biologics and 7 mentions for Valneva. ADMA Biologics' average media sentiment score of 0.93 beat Valneva's score of 0.55 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is VALN or ADMA more profitable? ADMA Biologics has a net margin of 44.06% compared to Valneva's net margin of -33.87%. ADMA Biologics' return on equity of 41.01% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-33.87% -34.78% -13.43% ADMA Biologics 44.06%41.01%28.47% Do insiders and institutionals have more ownership in VALN or ADMA? 11.4% of Valneva shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 3.5% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend VALN or ADMA? Valneva currently has a consensus price target of $15.00, indicating a potential upside of 57.07%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 82.26%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50ADMA Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, VALN or ADMA? ADMA Biologics has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$183.52M4.47-$13.25M-$0.98-9.74ADMA Biologics$426.45M8.49$197.67M$0.8617.65 SummaryADMA Biologics beats Valneva on 14 of the 17 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$820.60M$11.08B$6.21B$10.81BDividend YieldN/A1.88%5.72%4.80%P/E Ratio-9.7421.4531.6030.99Price / Sales4.4731.07595.06133.64Price / Cash97.7425.0837.2561.86Price / Book3.963.5012.056.61Net Income-$13.25M$210.63M$3.34B$277.10M7 Day Performance-5.08%0.74%1.94%2.57%1 Month Performance-1.65%2.73%6.88%3.20%1 Year Performance60.77%-7.76%56.06%33.22% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva3.1144 of 5 stars$9.55-1.3%$15.00+57.1%+60.8%$820.60M$183.52M-9.74700Analyst ForecastShort Interest ↓ADMAADMA Biologics3.6064 of 5 stars$14.69+2.3%$27.67+88.3%-4.0%$3.43B$426.45M17.08530News CoveragePositive NewsAnalyst DowngradeINDVIndivior2.0604 of 5 stars$24.29-0.8%$22.00-9.4%+179.2%$3.38B$1.17B39.181,051Upcoming EarningsAAPGAscentage Pharma Group InternationalN/A$35.31-0.4%N/AN/A$3.30B$134.35M0.00600Positive NewsXENEXenon Pharmaceuticals2.7366 of 5 stars$43.44+4.3%$53.67+23.5%-2.3%$3.21B$9.43M-12.24210QUREuniQure2.9678 of 5 stars$63.92+10.2%$71.75+12.2%+833.6%$3.18B$27.12M-16.31500Analyst ForecastGap UpZLABZai Lab2.7291 of 5 stars$28.74+1.6%$56.35+96.1%-18.7%$3.16B$398.99M-14.091,869News CoverageAnalyst ForecastAnalyst RevisionCGONCG Oncology2.1089 of 5 stars$43.59+5.1%$58.82+34.9%+20.0%$3.16B$1.14M-24.6361Analyst ForecastRAREUltragenyx Pharmaceutical4.4789 of 5 stars$34.40+5.4%$82.27+139.2%-37.7%$3.15B$560.23M-6.221,294News CoverageAnalyst ForecastIRONDisc Medicine2.8083 of 5 stars$87.17-3.1%$108.73+24.7%+86.1%$3.13BN/A-19.5030Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeAMRXAMNEAL PHARMACEUTICALS2.3981 of 5 stars$10.24+3.2%$12.00+17.2%+25.6%$3.12B$2.79B1,025.038,100Analyst Forecast Related Companies and Tools Related Companies ADMA Alternatives INDV Alternatives AAPG Alternatives XENE Alternatives QURE Alternatives ZLAB Alternatives CGON Alternatives RARE Alternatives IRON Alternatives AMRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
